Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?

Table 2 ICER for patients with the highest lifetime benefit-based treatment estimates and the highest 10-year risk-based treatment estimates

Cut-off value	5% of patients treated			10% of patients treated			20% of patients treated
	Costs	QALYs	ICER	Costs	QALYs	ICER	Costs	QALYs	ICER
No treatment	€111,727,411	65,897	-	€111,732,871	65,935	-	€111,620,058	65,893	-
Lifetime benefit-based treatment	€153,997,681	67,057	€36,440/QALY	€194,164,605	68,014	€39,650/QALY	€269,495,928	69,704	€41,426/QALY
10-year risk-based treatment	€153,071,526	66,755	€48,187/QALY	€192,212,131	67,443	€53,368/QALY	€266,326,909	68,846	€52,390/QALY

Costs and QALYs are given for the scenario of 10,000 patients
QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio

ISSN: 2397-7523